drugset / Trial / NCT03527966

rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures

NCT03527966

Phase 4 Terminated 3 enrolled Virtua Health, Inc.
RandomizedParallel-groupDouble-blindBasic science

Summary

This study is aimed at comparing the overall efficacy (clinical and radiographic) of Vivigen, a novel cellular allograft product, and rhBMP-2 when utilized in lumbar fusion procedures.

Timeline

Start
2017-07-03
Primary completion
2018-07-27
Completion
2018-07-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vivigen Cell therapy 5 ml
Comparator rhBMP-2 Protein / enzyme biologic